Skip to main content

Advertisement

Table 2 Efficacy of three artemisinin-containing combinations therapy in comparison with amodiaquine + sulphadoxine–pyrimethamine (AQ-SP) on day 28 after PCR correction, per-protocol analysis

From: Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial

   AS-SMP N = 54 AS-AQ N = 59 AL N = 52 AQ-SP N = 57 p-value
Per protocol analysis (with PCR correction)       
  ETF      
  n % (95% CI) 1 2% (0–10) 0 0% (0–6) 0 0% (0–7) 0 0% (0–6)  
  LCF      
  n % (95% CI) 2 4% (0–13) 3 5% (1–14) 2 4% (0–13) 0 0% (0–6)  
  LPF      
  n % (95% CI) 1 2% (0–10) 1 2% (0–9) 2 4% (0–13) 0 0% (0–6)  
  ACPR      0.133
  n % (95% CI) 50 93% (82–98) 55 93% (84–98) 52 92% (81–98) 57 100% (94–100)  
Intention to treat analysis (without PCR correction)       
  ETF      
  n % (95% CI) 1 2% (0–9) 0 0% (0–5) 0 0% (0–6) 0 0% (0–6)  
  LCF      
  n % (95% CI) 6 10% (4–21) 3 4% (1–12) 2 3%(0–12) 0 0% (0–6)  
  LPF      
  n % (95% CI) 1 2% (0–9) 1 1% (0–8) 3 5% (1–14) 1 2% (0–8)  
  ACPR      
  n % (95% CI) 48 83% (71–91) 55 81% (70–89) 48 80% (68–89) 57 88%(77–95) 0.058
  1. AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, Artesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine (Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective number; CI, Confidence interval.